[Management of MRSA-harboring patients: focused on mupirocin].
Inoue
M
M
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002353:Carrier State / Q000188:drug therapy* / Q000382:microbiology; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D016106:Methicillin Resistance; D016712:Mupirocin / Q000627:therapeutic use*; D009296:Nasal Cavity / Q000382:microbiology; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D016712:Mupirocin